Share-based Payment Arrangement, Expense of Werewolf Therapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Werewolf Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Werewolf Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,233,000, a 39% decline year-over-year.
  • Werewolf Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $6,940,000, a 21% decline year-over-year.
  • Werewolf Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8,826,000, a 10% increase from 2023.
  • Werewolf Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8,008,000, a 8.2% increase from 2022.
  • Werewolf Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,400,000, a 81% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Werewolf Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,940,000 $1,233,000 -$778,000 -39% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $7,718,000 $1,793,000 -$809,000 -31% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $8,527,000 $2,006,000 -$299,000 -13% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $8,826,000 $1,908,000 +$35,000 +1.9% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $8,791,000 $2,011,000 -$86,000 -4.1% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $8,877,000 $2,602,000 +$672,000 +35% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $8,205,000 $2,305,000 +$197,000 +9.3% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $8,008,000 $1,873,000 -$69,000 -3.6% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $8,077,000 $2,097,000 +$161,000 +8.3% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $7,916,000 $1,930,000 +$153,000 +8.6% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $7,763,000 $2,108,000 +$363,000 +21% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2024 2024 Q1
Q4 2022 $7,400,000 $1,942,000 +$646,000 +50% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q3 2022 $6,754,000 $1,936,000 +$457,000 +31% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $6,297,000 $1,777,000 +$996,000 +128% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $5,301,000 $1,745,000 +$1,206,000 +224% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $4,095,000 $1,296,000 +$1,075,000 +486% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $3,020,000 $1,479,000 +$1,346,000 +1012% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,674,000 $781,000 +$560,000 +253% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $1,114,000 $539,000 +$482,000 +846% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $632,000 $221,000 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $133,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $221,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $57,000 01 Jan 2020 31 Mar 2020 10-Q 10 Jun 2021 2021 Q1

Werewolf Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,826,000 +$818,000 +10% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $8,008,000 +$608,000 +8.2% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $7,400,000 +$3,305,000 +81% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $4,095,000 +$3,463,000 +548% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $632,000 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.